Shaoqiu Zhuo1, Robert L Wolfert2, Chong Yuan2. 1. Diazyme Laboratories, Inc., 12889 Gregg Ct., Poway, CA 92064, United States. Electronic address: shaoqiu.zhuo@bayer.com. 2. Diazyme Laboratories, Inc., 12889 Gregg Ct., Poway, CA 92064, United States.
Abstract
OBJECTIVES: There are two platforms for the detection of Lp-PLA2 in sera or plasmas: by its enzymatic activity (PLAC® activity test) and by its mass concentration (PLAC® mass test). It has been long recognized that these two platforms are not correlated well. The underlying cause for this is therefore investigated by the biochemical characterization of the two PLAC tests. DESIGN & METHODS: Human sera with and without the treatment by detergent were fractionated by using a Superose-6 column in phosphate buffered saline and the phospholipid associated Lp-PLA2 was assessed by both PLAC mass and activity tests. The Lp-PLA2 values of the two PLAC tests were compared under such conditions. RESULTS: Fractionation of sera and plasmas indicates that the association of Lp-PLA2 with phospholipids, especially LDL and other large size phospholipid vesicles, may block the detection of the enzyme by antibodies in the immunoassay format under the conditions of the PLAC mass test. Inclusion of high concentration (>CMC, critical micelle concentration) of detergents in the assay buffer of PLAC mass test dissociates Lp-PLA2 from phospholipid vesicles and results in the full detection of all Lp-PLA2 in sera or plasmas for concentration. Such assay modification significantly improves the correlation between the PLAC mass and PLAC activity tests. CONCLUSIONS: PLAC mass test only detects a small portion of the total Lp-PLA2, mainly the Lp-PLA2 associated with HDL. This is the main cause of the discordance and poor correlation between the PLAC mass and activity tests. Our results demonstrate the PLAC activity test is more accurate in assessing the total level of circulating Lp-PLA2.
OBJECTIVES: There are two platforms for the detection of Lp-PLA2 in sera or plasmas: by its enzymatic activity (PLAC® activity test) and by its mass concentration (PLAC® mass test). It has been long recognized that these two platforms are not correlated well. The underlying cause for this is therefore investigated by the biochemical characterization of the two PLAC tests. DESIGN & METHODS:Human sera with and without the treatment by detergent were fractionated by using a Superose-6 column in phosphate buffered saline and the phospholipid associated Lp-PLA2 was assessed by both PLAC mass and activity tests. The Lp-PLA2 values of the two PLAC tests were compared under such conditions. RESULTS: Fractionation of sera and plasmas indicates that the association of Lp-PLA2 with phospholipids, especially LDL and other large size phospholipid vesicles, may block the detection of the enzyme by antibodies in the immunoassay format under the conditions of the PLAC mass test. Inclusion of high concentration (>CMC, critical micelle concentration) of detergents in the assay buffer of PLAC mass test dissociates Lp-PLA2 from phospholipid vesicles and results in the full detection of all Lp-PLA2 in sera or plasmas for concentration. Such assay modification significantly improves the correlation between the PLAC mass and PLAC activity tests. CONCLUSIONS: PLAC mass test only detects a small portion of the total Lp-PLA2, mainly the Lp-PLA2 associated with HDL. This is the main cause of the discordance and poor correlation between the PLAC mass and activity tests. Our results demonstrate the PLAC activity test is more accurate in assessing the total level of circulating Lp-PLA2.
Authors: Moneeza K Siddiqui; Gillian Smith; Pamela St Jean; Adem Y Dawed; Samira Bell; Enrique Soto-Pedre; Gwen Kennedy; Fiona Carr; Lars Wallentin; Harvey White; Colin H Macphee; Dawn Waterworth; Colin N A Palmer Journal: Diabetologia Date: 2021-09-25 Impact factor: 10.122